Revolution, Ascendis, Arrowhead among RBC's top M&A candidates in biotech
Source: SeekingAlpha
2026-03-19 14:37:43 ET
More on Revolution Medicines, Ascendis Pharma, etc.
- Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
- Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL - Slideshow
- This One Data Readout Could Make Or Break Revolution Medicines
- Ascendis Pharma wins FDA approval for navepegritide for achondroplasia
- Kymera outlines plans for KT-621 Phase IIb data in 2027 as cash runway extends into 2029
Read the full article on Seeking Alpha
For further details see:
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
Pharvaris N.V.
NASDAQ: PHVS
PHVS Trading
1.78% G/L:
$26.28 Last:
28,342 Volume:
$25.65 Open:
PHVS Latest News
March 20, 2026 06:50:00 am
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
March 11, 2026 06:50:00 am
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
PHVS Stock Data
$1,492,567,159
37,790,994
N/A
37
N/A
Biotechnology & Life Sciences
Healthcare
NL
Leiden
